KR20240148426A - 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료 - Google Patents

2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료 Download PDF

Info

Publication number
KR20240148426A
KR20240148426A KR1020247030936A KR20247030936A KR20240148426A KR 20240148426 A KR20240148426 A KR 20240148426A KR 1020247030936 A KR1020247030936 A KR 1020247030936A KR 20247030936 A KR20247030936 A KR 20247030936A KR 20240148426 A KR20240148426 A KR 20240148426A
Authority
KR
South Korea
Prior art keywords
amount
subject
administration
cyclodextrin
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030936A
Other languages
English (en)
Korean (ko)
Inventor
제이슨 캠
Original Assignee
베렌 테라퓨틱스 피.비.씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베렌 테라퓨틱스 피.비.씨. filed Critical 베렌 테라퓨틱스 피.비.씨.
Publication of KR20240148426A publication Critical patent/KR20240148426A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020247030936A 2022-02-18 2023-02-17 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료 Pending KR20240148426A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311536P 2022-02-18 2022-02-18
US63/311,536 2022-02-18
PCT/IB2023/051467 WO2023156970A1 (en) 2022-02-18 2023-02-17 Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Publications (1)

Publication Number Publication Date
KR20240148426A true KR20240148426A (ko) 2024-10-11

Family

ID=85476260

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030936A Pending KR20240148426A (ko) 2022-02-18 2023-02-17 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료

Country Status (11)

Country Link
US (1) US20240398849A1 (https=)
EP (1) EP4479064A1 (https=)
JP (1) JP2025508660A (https=)
KR (1) KR20240148426A (https=)
CN (1) CN118715017A (https=)
AU (1) AU2023222567A1 (https=)
CA (1) CA3244447A1 (https=)
IL (1) IL315046A (https=)
MX (1) MX2024010110A (https=)
TW (1) TW202342072A (https=)
WO (1) WO2023156970A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307518A (pt) * 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
CN1745746A (zh) * 2004-09-09 2006-03-15 天津药物研究院 冰片的羟丙基－β－环糊精包合物及其制剂和制备方法
CN1961892A (zh) * 2005-11-08 2007-05-16 天津药物研究院 降香羟丙基－β－环糊精包合物及其制剂和制备方法
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
JP5847721B2 (ja) * 2009-10-08 2016-01-27 ソン、ホ、バイオメッド、カンパニー、リミテッドＳｏｎｇ Ｈｏ Ｂｉｏｍｅｄ Ｃｏ．， Ｌｔｄ 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Also Published As

Publication number Publication date
IL315046A (en) 2024-10-01
WO2023156970A1 (en) 2023-08-24
JP2025508660A (ja) 2025-04-10
AU2023222567A1 (en) 2024-09-19
US20240398849A1 (en) 2024-12-05
CA3244447A1 (en) 2023-08-24
MX2024010110A (es) 2024-08-30
EP4479064A1 (en) 2024-12-25
TW202342072A (zh) 2023-11-01
CN118715017A (zh) 2024-09-27

Similar Documents

Publication Publication Date Title
KR20160033796A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
JP7835735B2 (ja) シクロデキストリンによるコレステロール結晶塞栓症の治療方法
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
US20240082242A1 (en) Combination therapies
KR20240148426A (ko) 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료
US20230091966A1 (en) Methods for the treatment of cardiovascular disease with cyclodextrins
US20220260597A1 (en) Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
US7008934B2 (en) Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
US20230302042A1 (en) Methods for the prevention of cholesterol crystal embolization with cyclodextrins
CN119157896A (zh) 烟酰胺单核苷酸用于制备预防或治疗NT-proBNP异常的药物的应用
KR20100051653A (ko) 관동맥의 묘출능 개선제

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000